Genentech

We heard 2016 was trending… At the American Academy of Neurology Annual Meeting, we surprised members of our neuroimmunology team with their photos from 2016 and asked them to reflect on the progress of the past decade—and what the next 10 years may bring in multiple sclerosis (MS). Their reactions offer a glimpse into our MS research journey. Driven by purpose, inspired by the patient community, and continuously evolving. Hear from Erik Lundgren, MBA, Eugene An and Ashish Pradhan as they share perspectives on where we were, where we are, and where we’re headed in MS research and development. #AANAM #Neurology #MultipleSclerosis

We’re bringing more attention to diabetic macular edema (DME), an often overlooked eye condition associated with diabetes that impacts vision, and disproportionately affects Black adults. We’re proud to introduce All Eyes on DME, an initiative focused on raising awareness and supporting people living with diabetes in prioritizing their vision care. Learn more: http://spr.ly/6044BB1fxe

Advancing understanding in rare diseases like myelin oligodendrocyte glycoprotein antibody disease (MOGAD) requires continued research and collaboration. Julia Lefelar, co-founder and Executive Director of The MOG Project, shares why this work matters for the MOGAD community. #MOGADAwarenessMonth #AANAM

#Breaking: We are excited to share positive results from our Phase III trials evaluating our investigational BTK inhibitor in people living with relapsing multiple sclerosis (RMS). For the more than 2.9 million people living with multiple sclerosis (MS) worldwide, this data brings our research and development strides into focus, representing a potential new approach to MS with comprehensive disease control. Learn more: http://spr.ly/6046BB8uD8

#Breaking: Today at #AANAM we’re presenting the first-ever positive Phase III results in myelin oligodendrocyte glycoprotein antibody disease (MOGAD), a rare and debilitating autoimmune disease of the central nervous system. http://spr.ly/6048BBBmyE

The FDA accepted our supplemental Biologics License Application for our medicine to treat systemic lupus erythematosus (SLE). SLE, the most common form of #lupus, is a potentially life-threatening autoimmune disease affecting more than 3 million people worldwide. There’s a critical need for a treatment option that can help reduce the daily impact of the disease on patients and has the potential to reduce steroid use. If approved, our medicine has the potential to offer an option to manage this disease. Learn more: http://spr.ly/6049BBBrYT

In multiple sclerosis (MS), immune-driven inflammation plays a central role in how the disease progresses over time. Advancing our understanding of this biology is critical. BTK inhibitors are being studied for their potential to more precisely target this underlying immune activity, with the goal of helping preserve brain function across forms of MS. Learn more about our scientific approach: http://spr.ly/6047B6ApVd

This week at the American Academy of Neurology (AAN) Annual Meeting, we’ll be sharing new data from our neurology portfolio, including multiple sclerosis (MS) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), with Roche. AAN is an opportunity to engage with the scientific community, share insights, and contribute to the journey of innovation – a sentiment deeply appreciated by Hideki Garren, SVP Global Head of Clinical Development, Neurology, on behalf of the #MS and #MOGAD communities. Learn more about the complexity of neurological conditions and how we are working to better understand them here: http://spr.ly/6041B6h9JB #AANAM #Neurology

Our understanding of multiple sclerosis (MS) continues to evolve rapidly. In our recent episode of Two Scientists Walk Into a Bar, Sherman Jia discusses emerging insights into the underlying biology of MS, including what new research is revealing about disease progression and the potential of next-generation therapies. Explore the latest developments shaping the future of MS research wherever you listen to #podcasts. http://spr.ly/6044B6NYBG

Across many rural communities, including in West Texas, challenges accessing healthcare is a daily reality – from long travel distances and provider shortages to gaps in specialty care. That’s why we convened local providers, patient groups and national partners for a Permian Basin Rural Health Summit where we listened, learned and co-created practical solutions. And this isn’t a one-time conversation. It’s part of our ongoing effort to support long-term, sustainable progress so more people living in rural communities can reliably access the care they need. As healthcare market executive director Donishea Martinez puts it, “We believe that where you live should not determine how long you live.” A huge thanks to our local partners for making this event, and more importantly, efforts to advance a more accessible healthcare system, possible: Texas Tech University Health Sciences Center, Texas Oncology, Odessa Regional Medical Center, Midland Memorial Hospital. Learn more below.